These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36797067)

  • 1. Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3.
    Tezenas du Montcel S; Petit E; Olubajo T; Faber J; Lallemant-Dudek P; Bushara K; Perlman S; Subramony SH; Morgan D; Jackman B; Figueroa KP; Pulst SM; Fauret-Amsellem AL; Dufke C; Paulson HL; Öz G; Klockgether T; Durr A; Ashizawa T;
    Neurology; 2023 Apr; 100(17):e1836-e1848. PubMed ID: 36797067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.
    Wilke C; Mengel D; Schöls L; Hengel H; Rakowicz M; Klockgether T; Durr A; Filla A; Melegh B; Schüle R; Reetz K; Jacobi H; Synofzik M
    Neurology; 2022 May; 98(20):e1985-e1996. PubMed ID: 35264424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
    Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY
    Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers.
    Coarelli G; Dubec-Fleury C; Petit E; Sayah S; Fischer C; Nassisi M; Gatignol P; Dorgham K; Daghsen L; Daye P; Cunha P; Kacher R; Hilab R; Hurmic H; Lamazière A; Lamy JC; Welter ML; Chupin M; Mangin JF; Lane R; Gaymard B; Pouget P; Audo I; Brice A; Tezenas du Montcel S; Durr A
    Neurology; 2024 Sep; 103(5):e209749. PubMed ID: 39133883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia.
    Coarelli G; Darios F; Petit E; Dorgham K; Adanyeguh I; Petit E; Brice A; Mochel F; Durr A
    Neurobiol Dis; 2021 Jun; 153():105311. PubMed ID: 33636389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.
    Jacobi H; du Montcel ST; Romanzetti S; Harmuth F; Mariotti C; Nanetti L; Rakowicz M; Makowicz G; Durr A; Monin ML; Filla A; Roca A; Schöls L; Hengel H; Infante J; Kang JS; Timmann D; Casali C; Masciullo M; Baliko L; Melegh B; Nachbauer W; Bürk-Gergs K; Schulz JB; Riess O; Reetz K; Klockgether T
    Lancet Neurol; 2020 Sep; 19(9):738-747. PubMed ID: 32822634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3.
    Chandrasekaran J; Petit E; Park YW; du Montcel ST; Joers JM; Deelchand DK; Považan M; Banan G; Valabregue R; Ehses P; Faber J; Coupé P; Onyike CU; Barker PB; Schmahmann JD; Ratai EM; Subramony SH; Mareci TH; Bushara KO; Paulson H; Durr A; Klockgether T; Ashizawa T; Lenglet C; Öz G;
    Ann Neurol; 2023 Apr; 93(4):686-701. PubMed ID: 36511514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.
    Garcia-Moreno H; Prudencio M; Thomas-Black G; Solanky N; Jansen-West KR; Hanna Al-Shaikh R; Heslegrave A; Zetterberg H; Santana MM; Pereira de Almeida L; Vasconcelos-Ferreira A; Januário C; Infante J; Faber J; Klockgether T; Reetz K; Raposo M; Ferreira AF; Lima M; Schöls L; Synofzik M; Hübener-Schmid J; Puschmann A; Gorcenco S; Wszolek ZK; Petrucelli L; Giunti P
    Eur J Neurol; 2022 Aug; 29(8):2439-2452. PubMed ID: 35478426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.
    Jacobi H; Reetz K; du Montcel ST; Bauer P; Mariotti C; Nanetti L; Rakowicz M; Sulek A; Durr A; Charles P; Filla A; Antenora A; Schöls L; Schicks J; Infante J; Kang JS; Timmann D; Di Fabio R; Masciullo M; Baliko L; Melegh B; Boesch S; Bürk K; Peltz A; Schulz JB; Dufaure-Garé I; Klockgether T
    Lancet Neurol; 2013 Jul; 12(7):650-8. PubMed ID: 23707147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.
    Wilke C; Haas E; Reetz K; Faber J; Garcia-Moreno H; Santana MM; van de Warrenburg B; Hengel H; Lima M; Filla A; Durr A; Melegh B; Masciullo M; Infante J; Giunti P; Neumann M; de Vries J; Pereira de Almeida L; Rakowicz M; Jacobi H; Schüle R; Kaeser SA; Kuhle J; Klockgether T; Schöls L; ; Barro C; Hübener-Schmid J; Synofzik M
    EMBO Mol Med; 2020 Jul; 12(7):e11803. PubMed ID: 32510847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography.
    Chen Z; Liao G; Wan N; He Z; Chen D; Tang Z; Long Z; Zou G; Peng L; Wan L; Wang C; Peng H; Shi Y; Tang Y; Li J; Li Y; Long T; Hou X; He L; Qiu R; Chen D; Wang J; Guo J; Shen L; Huang Y; Ashizawa T; Klockgether T; Tang B; Zhou M; Hu S; Jiang H
    Mov Disord; 2023 Jun; 38(6):978-989. PubMed ID: 37023261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of Clinical and Eye Movement Markers in Preataxic Carriers of Machado-Joseph Disease.
    de Oliveira CM; Leotti VB; Cappelli AH; Rocha AG; Ecco G; Bolzan G; Kersting N; Saraiva-Pereira ML; Jardim LB
    Mov Disord; 2023 Jan; 38(1):26-34. PubMed ID: 36129443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic assessment of plasma biomarkers in spinocerebellar ataxia.
    Shen XN; Wu KM; Huang YY; Guo Y; Huang SY; Zhang YR; Chen SF; Wang HF; Zhang W; Cheng W; Cui M; Dong Q; Yu JT
    Neurobiol Dis; 2023 Jun; 181():106112. PubMed ID: 37003406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive-affective manifestations since premanifest phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
    Bolzan G; Müller Eyng ME; Leotti VB; Saraiva-Pereira ML; Jardim LB
    Cortex; 2024 Feb; 171():370-382. PubMed ID: 38091940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood transcriptome sequencing identifies biomarkers able to track disease stages in spinocerebellar ataxia type 3.
    Raposo M; Hübener-Schmid J; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; ; Riess O; Lima M
    Brain; 2023 Oct; 146(10):4132-4143. PubMed ID: 37071051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-ataxic Changes of Clinical Scales and Eye Movement in Machado-Joseph Disease: BIGPRO Study.
    de Oliveira CM; Leotti VB; Bolzan G; Cappelli AH; Rocha AG; Ecco G; Kersting N; Rieck M; Martins AC; Sena LS; Saraiva-Pereira ML; Jardim LB
    Mov Disord; 2021 Apr; 36(4):985-994. PubMed ID: 33438269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3.
    Faber J; Schaprian T; Berkan K; Reetz K; França MC; de Rezende TJR; Hong J; Liao W; van de Warrenburg B; van Gaalen J; Durr A; Mochel F; Giunti P; Garcia-Moreno H; Schoels L; Hengel H; Synofzik M; Bender B; Oz G; Joers J; de Vries JJ; Kang JS; Timmann-Braun D; Jacobi H; Infante J; Joules R; Romanzetti S; Diedrichsen J; Schmid M; Wolz R; Klockgether T
    Mov Disord; 2021 Oct; 36(10):2273-2281. PubMed ID: 33951232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-dependent biomarker changes in spinocerebellar ataxia type 3.
    Faber J; Berger M; Carlo W; Hübener-Schmid J; Schaprian T; Santana MM; Grobe-Einsler M; Onder D; Koyak B; Giunti P; Garcia-Moreno H; Gonzalez-Robles C; Lima M; Raposo M; Melo ARV; de Almeida LP; Silva P; Pinto MM; van de Warrenburg BP; van Gaalen J; de Vries J; Jeroen ; Oz G; Joers JM; Synofzik M; Schöls L; Riess O; Infante J; Manrique L; Timmann D; Thieme A; Jacobi H; Reetz K; Dogan I; Onyike C; Povazan M; Schmahmann J; Ratai EM; Schmid M; Klockgether T
    medRxiv; 2023 Apr; ():. PubMed ID: 37163081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of the CAG Triplet Repeat in ATXN1, ATXN3, and CACNA1A Loci in Peruvian Population.
    Gonzales-Sáenz C; Cruz-Rodriguez C; Espinoza-Huertas K; Véliz-Otani D; Marca V; Ortega O; Milla-Neyra K; Alvarez-Tejada J; Mazzetti P; Cornejo-Olivas M
    Cerebellum; 2020 Aug; 19(4):527-535. PubMed ID: 32285347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of Advanced Magnetic Resonance Imaging to Progression over Six Months in Early Spinocerebellar Ataxia.
    Rezende TJR; Petit E; Park YW; Tezenas du Montcel S; Joers JM; DuBois JM; Moore Arnold H; Povazan M; Banan G; Valabregue R; Ehses P; Faber J; Coupé P; Onyike CU; Barker PB; Schmahmann JD; Ratai EM; Subramony SH; Mareci TH; Bushara KO; Paulson H; Klockgether T; Durr A; Ashizawa T; Lenglet C; Öz G;
    Mov Disord; 2024 Oct; 39(10):1856-1867. PubMed ID: 39056163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.